AAAAAA

   
Results: 1-3 |
Results: 3
Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: A role for altered tumor angiogenesis
Authors: Viloria-Petit, A Crombet, T Jothy, S Hicklin, D Bohlen, P Schlaeppi, JM Rak, J Kerbel, RS
Citation: A. Viloria-petit et al., Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: A role for altered tumor angiogenesis, CANCER RES, 61(13), 2001, pp. 5090-5101
Characterization of a new potent, in vivo neutralizing monoclonal antibodyto human vascular endothelial growth factor
Authors: Schlaeppi, JM Siemeister, G Weindel, K Schnell, C Wood, J
Citation: Jm. Schlaeppi et al., Characterization of a new potent, in vivo neutralizing monoclonal antibodyto human vascular endothelial growth factor, J CANC RES, 125(6), 1999, pp. 336-342
Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors
Authors: Schlaeppi, JM Wood, JM
Citation: Jm. Schlaeppi et Jm. Wood, Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors, CANC METAST, 18(4), 1999, pp. 473-481
Risultati: 1-3 |